Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Julia Quintanilha


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


J.C.F. Quintanilha1, A. Racioppi2, J. Wang3, S. Denning4, A.S. Etheridge4, C.E. Peña5, D.J. Crona4, D. Lin3, F. Innocenti4

Author affiliations

  • 1 Division Of Pharmacotherapy And Experimental Therapeutics, UNC-Institute for Pharmacogenomics and Individualized Therapy, 27599 - Chapel Hill/US
  • 2 Division Of Pharmacotherapy And Experimental Therapeutics, University of North Carolina, 27599 - Chapel Hill/US
  • 3 Department Of Biostatistics, University of North Carolina, Chapel Hill/US
  • 4 Division Of Pharmacotherapy And Experimental Therapeutics, University of North Carolina, 27514 - Chapel Hill/US
  • 5 Bayer Healthcare Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Whippany/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2591


Hypertension is one of the major side effect of VEGF-pathway inhibitors. There are no validated biomarkers to predict which cancer patients will develop hypertension. This study aimed to identify genetic predictors of hypertension induced by VEGF-pathway inhibitors.


A two-step, discovery-validation approach was used. The discovery set included 140 renal cell carcinoma patients from the TARGET study treated with sorafenib (400 mg twice daily) (PMID 30385613) and genotyped for 1,040 germline variants in 56 genes. The most statistically significant variant from the discovery set (chi-squared test) was tested in a validation set (cause-specific Cox model) consisting of 1,041 cancer patients treated with bevacizumab (10-15 mg/kg every two-three weeks) and genotyped using GWAS microarray platforms. For both studies, grade ≥2 hypertension (CTCAE v. 3.0) was used as the endpoint. Genetic associations were adjusted for age and sex.


In the discovery set, the most statistically significant variant associated with hypertension in sorafenib-treated patients was rs444904 (G>A, P = 0.006). The A allele of rs444904 (minor allele frequency, MAF 0.14) increased the risk of hypertension. In the validation set, the A allele of rs427554 (G>A, in complete linkage disequilibrium with rs444904) increased the risk of hypertension in bevacizumab-treated patients (P = 0.008, MAF 0.11). rs444904 and rs427554 are intronic variants in PIK3R5. PIK3R5 encodes the regulatory subunit of PI3Kγ, which, when activated by VEGF, leads to nitric oxide (NO) production and vasodilation. These variants have been associated with decreased expression of PIK3R5 in blood (PMID 25954001), consistent with their effect in increasing the risk of hypertension.


Common genetic variants that could reduce PIK3R5 activity increase the risk of sorafenib- and bevacizumab-induced hypertension. In patients treated with these drugs, reduced activity or expression of PIK3R5 may lead to a reduction in NO production, resulting in vasoconstriction and hypertension. This study, for the first time, provides evidence for new predictive genetic markers of drug-induced hypertension that should be further evaluated for other VEGF-pathway inhibitors.

Clinical trial identification

TARGET CALGB 80303 NCT00088894 CALGB 40503 NCT00601900 CALGB 40502 NCT00785291 CALGB 90401 NCT00110214.

Editorial acknowledgement

Legal entity responsible for the study

Federico Innocenti.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.